NFkB P52 Peptid

Application Note: Control peptide should be used at 1.0 μg per 1.0 μL of antiserum in per assay.

Other: Control peptide should be used at 1.0 μg per 1.0 μL of antiserum per assay. 

Buffer: None

Stabilizer: None

Synonyms: NFKB p52 Peptide, Nuclear factor NF-kappa-B p105 subunit, DNA-binding factor KBF1, EBP-1 antibody, control peptide, blocking peptide

Background: Intended for use as a control peptide when used with anti-NFkB p52 to block specific interaction of anti-NFkB p52 (p/n 100-4185) with the NFkB p52. NFkB was originally identified as a factor that binds to the immunoglobulin kappa light chain enhancer in B cells. It was subsequently found in non-B cells in an inactive cytoplasmic form consisting of NFkB bound to IkB. NFkB was originally identified as a heterodimeric DNA binding protein complex consisting of p65 (RelA) and p50 (NFKB1) subunits. Other identified subunits include p52 (NFKB2), c-Rel, and RelB. The p65, cRel, and RelB subunits are responsible for transactivation. The p50 and p52 subunits possess DNA binding activity but limited ability to transactivate. p52 has been reported to form transcriptionally active heterodimers with the NFkB subunit p65, similar to p50/p65 heterodimers. The heterodimers of p52/p65 and p50/p65 are regulated by physical inactivation in the cytoplasm by IkB-a. IkB-a binds to the p65 subunit, preventing nuclear localization and DNA binding. Low levels of p52 and p50 homodimers can also exist in cells.